Boletín administrativo: 2026-07-004 Actualizaciones de farmacias

Date: July 1, 2026

Effective date: July 1, 2026

Los temas tratados en este boletín administrativo aplican a:

Proveedores profesionales y de centros

Proveedores profesionales y de centros

Capital Blue Cross formulary update – Dapagliflozin replaces Farxiga

  • CHIP
  • EPO
  • FEP PPO
  • HMO
  • Medicare Advantage HMO
  • POS
  • PPO
  • Tradicional e Integral
  • Medicare Advantage PPO

KEY POINT: Effective July 1, 2026, Farxiga has been removed, and the alternative, dapagliflozin has been added to the Capital Blue Cross Elite and Exclusive, Advantage, and Value Plus Formularies.

The following update reflects a change to previously published information regarding Capital’s July formulary updates. For the complete list, please refer to the May 2026 publication, Administrative bulletin 2026-05-004 Pharmacy updates.

Actualización del listado de medicamentos de Capital Blue Cross

KEY: (PA) = Prior Authorization; (ST) = Step therapy; (QLL) = Quantity Level Limits lowercase bold print = generic; UPPERCASE PRINT = BRAND Formulary Status: Generic Preferred (GP), Generic Non-Preferred (GNP), Brand Preferred (BP), Brand Non-Preferred (BNP), Nonformulary (NF)
Removed from formulary effective July 1, 2026

Nombre de marca

Estado del nivel

Indicación 

Preferred alternative

FARXIGA

BP

Antidiabetes

dapagliflozin (ST, QLL)